HPV vaccine response study for people living with HIV
Treatments studied
Part of Cancer, Immune system & allergy, Infections, Women’s health & pregnancy clinical trials.
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV.
- Your recent CD4 count (a type of immune cell) is above 200.
- Your recent HIV viral load is controlled and below 1,000 copies.
- You have been on the same HIV medicines (antiretroviral regimen) for at least 3 months.
- You are either vaccine-naive and age 45 or younger, or you already completed 3 doses of Gardasil-4 or Gardasil-9.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a lower dose of the HPV vaccine can still be effective and safe for women living with HIV. It may be helpful if you need HPV protection and the study’s dose schedule could reduce vaccine burden.
This study tests how well the Gardasil 9 HPV vaccine works in people assigned male at birth, including those with HIV and those taking hormone therapy. Results could help protect against HPV-related cancers.
This study tests if a single dose of the HPV vaccine (Gardasil 9) can lower the amount of HPV virus in women who already have the virus, potentially reducing how easily it spreads. It will help us learn if vaccination can protect partners and communities.
This study looks at how well the HPV vaccine works in women living with HIV and whether it helps make cervical cancer screening more accurate. If you are a woman with HIV between 21 and 40 years old and already part of certain other HIV studies, you may be able to join.
This trial tests whether adding HPV vaccination to the cervical cancer screening plan—while you get care at HIV (ARV) clinics—improves prevention of cervical problems. It focuses on women with HIV aged 25–35 to help reduce HPV-related cervical disease over time.
This trial tests how well the HPV vaccine triggers immune memory in women who may have been exposed to HPV. It could help protect against future HPV infections and related cancers.
Hear when a new Papillomavirus Vaccines trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.